DEBORAH MONAHAN: Open Payments
NPI 1215200613 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$627 in 18 payments from 8 companies in 2025. Trend: 2023 $105 · 2024 $320 · 2025 $627
Food & beverage: $627
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 2 | $289 |
| PFIZER INC. | 5 | $102 |
| Eisai Inc. | 4 | $88 |
| Novartis Pharmaceuticals Corporation | 3 | $53 |
| ABBVIE INC. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| ARRAY BIOPHARMA INC | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $21 |
Products named: SARCLISA, Lenvima, IBRANCE, SCEMBLIX, PADCEV, IMBRUVICA, Cresemba, XALKORI.
Industry payments across WA — which companies pay providers there.
